iProstate Cancer Foundation Annual Report 04

1250 Fourth Street Santa Monica, California 90401 Tel 310.570.4700 Fax 310.570.4701 www.prostatecancerfoundation.org Donations

Please mail your check to: Prostate Cancer Foundation 1250 Fourth Street Santa Monica, California 90401

To make an online contribution, please visit our Web site: prostatecancerfoundation.org.

To make a credit card donation, call 800.757.CURE.

Memorial or Tribute Gifts

Honor the memory of a loved one or celebrate the accomplish- ment of a friend or family PCF member by helping others. 2004 WAS A REMARKABLE YEAR. Make a memorial or tribute gift and the PCF will send an Fortune featured the PCF in its November cover story acknowledgment card to the entitled “Beating Cancer,” and named the PCF as its offi cial family of the honoree. philanthropy to celebrate its 75th anniversary. Other Gift Suggestions For the fi rst time ever, the U.S. Food and Drug Adminis- tration approved a drug (Taxotere) that extends life for men Assets or property including with advanced prostate cancer. appreciated stock and real estate.

The PCF expanded its donor base by 35%. Bequest—Include a gift to the PCF in your will. And, signifi cant progress was made in demonstrating the link between nutrition, especially antioxidants, and Name the PCF as the primary prostate cancer. or contingent benefi ciary on a life insurance policy.

Editors: Sarah Evans, Jessica Niebauer Contributor: Jon Greer Special Thanks: Aaron Ciechanover, M.D., D.Sc., Steve Burd, Don Coffey, Ph.D. , Rosey Grier, Beth Kobliner Shaw, Nelson Peltz, Marvin R. Shanken, Wade F.B. Thompson, Joe Torre Photography: Michael D’Ambrosia Design: KBDA, Los Angeles More information: www.prostatecancerfoundation.org Fortune magazine noted the PCF and Mike Milken have…

“…managed to raise the profi le of prostate cancer signifi cantly, increase funding dramatically to fi ght the dis- ease, spur innovative research, attract new people to the fi eld, get myriad drugs into clinical trials, and dare we say, speed up science.”

November 29, 2004 2Prostate Cancer Foundation

DEAR FRIENDS Last spring, Fortune magazine arrived on our desks with a dispiriting cover story titled “Why We’re Losing the War on Cancer.” The article argued that the “cancer establishment” was wasting time and resources while millions of cancer patients were left waiting for new treatments and a cure for their disease.

While we respected Fortune’s took our advice, and the We have funded more than analysis, it simply didn’t resulting cover story ran in 1,200 prostate cancer research square with what we were November 2004 under the projects at more than 100 experiencing at the Prostate headline “Beating Cancer.” institutions worldwide. We Cancer Foundation. Here, have successfully advocated Harnessing Our Power we saw the best and brightest for massive increases in federal researchers making real strides At the PCF, we are doing funding for prostate cancer in understanding this disease everything in our power to research, leveraging your con- and testing new treatments. beat cancer. Starting a little tributions many times over. We were identifying visionary more than a decade ago, we Moreover, we have contin- leaders working relentlessly to turned the “cancer establish- uously worked to clear the remove roadblocks to the de- ment” on its ear, transforming barriers to successful prostate velopment of better treatments prostate cancer research from cancer research. We have and potential cures. And, we a backwater into one of the established novel alliances were researching treatments most important areas of cancer among research institutions and lifestyle changes available research. We have raised more and bridged the gap between to patients right now, helping than $230 million from major clinicians in the various medi- many live longer. donors, corporations, leading cal disciplines, providing them brands and individuals to We felt so strongly, in fact, that with valuable insight into the fund prostate cancer research, we suggested to Fortune that research process and gaining quickly establishing the PCF they do a follow-up story on their help in speeding prostate as the world’s leading phil- the success of the PCF. They anthropic source of support for prostate cancer research. 3

cancer treatments through through the clinical pipeline the development process. toward regulatory approval. We have opened doors to key In 1993, men without prostate government offi cials, provid- cancer didn’t have their pros- ing them with information tate specifi c antigen (PSA) and support to both rally levels routinely checked governmental resources and because the test wasn’t even reduce bureaucratic barriers. approved as a preventive screening method. Today, Achieving Results tens of millions of men have

In 2004, we issued the fi rst- their PSA levels checked, ever Report to the Nation on allowing physicians to catch Today, breakthroughs in Prostate Cancer, in which 24 prostate cancer at very early prostate cancer research seem prostate cancer thought leaders stages while also increasing to happen almost daily, with outlined the state of the art in treatment options. new reports streaming out the diagnosis, treatment and Today, breakthroughs in about advances in drug devel- prevention of prostate cancer prostate cancer research seem opment, treatment options, and laid out a clear agenda to happen almost daily, with diagnostic capabilities and for future progress. new reports streaming out new lifestyle choices. The results? We are fi ghting about advances in drug devel- cancer in meaningful ways. opment, treatment options, In 2004, an estimated 30,000 diagnostic capabilities and men died of prostate cancer, new lifestyle choices. A recent a 26% decrease in prostate pinnacle of scientifi c achieve- cancer deaths from 1993, ment was reached with the when the PCF was founded. awarding of the 2004 Nobel In 1993, there were fi ve Prize in Chemistry to Aaron approved drugs for treating Ciechanover, M.D., D.Sc., a prostate cancer. Today there recipient of multiple PCF are 13 approved drugs, with research grants, to support many more making their way his award-winning research into the proteasome, which regulates the abundance of key proteins involved in cell survival. 4 Prostate Cancer Foundation

A Team Effort are likely to die from prostate This year, we urge you cancer in 2005. Moreover, to act and help the Prostate Indeed, it’s a very exciting with the aging of the baby Cancer Foundation continue time to be working on your boomer generation, we await to beat cancer. behalf to fi nd better treat- a wave of new prostate cancer ments and an ultimate cure Sincerely, cases, upwards of 300,000 a for recurrent prostate cancer. year by 2015, and a death rate We have been joined in our spiraling up to 50,000 men Michael Milken work by an impressive lineup per year. Founder and Chairman of supporters, including Major League Baseball, Safeway, These sobering statistics eBay, AriZona Beverages, guide us in everything we do. Yahoo!, News Corp., Hugo If we are to continue to beat Boss and many more. We prostate cancer, we will have have persuaded the two most to marshal far more resources populous states in the U.S., and persuade many more New York and California, to people to join our cause. include a tax-form check-off That’s why we continue to to support prostate cancer. need your help. We’re doing Leslie D. Michelson We have generated a wave of Vice Chairman and everything we possibly can, publicity about our cause with Chief Executive Offi cer around the clock, to beat the help of NBC’s Today show; cancer—raising funds, sup- our “Act. Like a Man.” public porting researchers, breaking service advertising campaign, down barriers, creating produced by TBWA\Chiat\ alliances—but to do more, Day; and, yes, a cover story we must have your help. in Fortune magazine.

You Must Act Yet we stay focused on our goal, and for a very good With your generous support, reason: In 2005, an estimated we can fund more of the 232,000 men will be diag- many worthy research grant nosed with prostate cancer. requests that arrive at our Despite all our achievements offi ces every day. With your to date, another 30,000 men help, we will continue to clear the scientifi c and bureaucratic hurdles that impede progress and cause needless suffering. We can’t do it alone. It’s as simple as that. To beat prostate cancer once and for all, we must leverage the talents and resources of thousands of people and institutions around the world. Collaboration, cooperation and teamwork have been hallmarks of the PCF from the start, and they remain important components of the PCF’s ongoing strategy. Our sup- porters include the people featured in this report—men with prostate cancer, loved ones and others who simply care. Join us. 6Prostate Cancer Foundation

PROSTATE CANCER Cancer of the prostate is the most common non-skin cancer STATUS UPDATE in America. One in six American men will be diagnosed with prostate cancer. A man is 33% more likely to get prostate cancer than a woman is to get breast cancer.

Prostate cancer is a scourge—it attacks millions of men as they age. Last year, 232,000 men received a prostate cancer diagnosis, and the disease took the lives of some 30,000 men, including the famous—Law & Order’s Jerry Orbach, Citigroup’s Walter Wriston, legendary guitarist Johnny Ramone—as well as everyday loved ones—someone’s father, son, brother, friend.

The prostate is no bigger than a walnut, yet it plays a key role in the male reproductive system. Located in a hard-to-reach place between the penis and the bladder, it is unusually susceptible to cancer. Researchers believe the “Western-style” The Likelihood of Developing diet of the average American—high in fat but low in fruits Prostate Cancer Increases Dramatically with Age and vegetables—may be partly responsible for the high rates of prostate cancer in the U.S. compared with those of other Age Likelihood nations. That’s one reason the PCF emphasizes nutrition and lifestyle research. Prostate cancer also has the strongest familial link among all major cancers. Twenty-fi ve percent of prostate cancer patients have a relative with the disease. Race is also a 0–39 less than 1% factor—African Americans are 65% more likely to develop prostate cancer compared with Caucasians, and are twice as likely to die from it.

40–59 3% While we still don’t know what causes prostate cancer, we do know that as men get older, their chances of developing the disease rise sharply. With thousands of baby boomers turning 50 every single day, the cohort of men who will get prostate cancer is growing rapidly. So the PCF considers itself to be in 60–79 14% a race against time to develop better treatments and a cure for recurrent prostate cancer as soon as possible.

Overall 17%

Source: American Cancer Society, Cancer Facts and Figures, 2005. “ I ’ve never seen a harder-working team than the people at the PCF. Their commitment to winning the fi ght against this disease is matched only by their desire to save lives.” NAME Joe Torre

AGE 64

OCCUPATION Four-time World Series champion and Manager, New York Yankees

PCF CONNECTION An infl uential leader in the PCF’s Home Run Challenge, Joe is a spokesman, public advocate and role model for the PCF.

“ New treatments and early detection are saving lives, but the fi ght won’t be over until we fi nd a cure. The PCF is doing more than any other group to see to it that we win this battle.”

10 Prostate Cancer Foundation

Currently, there are 13 In the 11 years of the PCF’s existence, leading-edge prostate approved drugs to treat cancer diagnosis, treatment and prevention have come a long prostate cancer, more than way. Today, there are two primary screening methods for double the number available prostate cancer: digital rectal exam and the PSA blood test. In when the PCF opened addition, a battery of treatment options are available including its doors. removal of the prostate (radical prostatectomy) and radiation treatment (external beam or brachytherapy) for localized prostate cancer. Treatment options for advanced or metastatic prostate cancer include hormone therapy and chemotherapy. Currently, there are 13 approved drugs to treat prostate cancer, more than double the number available when the PCF opened its doors.

Moreover, there are scores of new drugs and novel treatment options in various stages of research and development for the treatment and management of prostate cancer, many of them funded by the PCF. The PCF is committed to bringing new drugs and treatment options through the regulatory process and into the hands of practicing physicians as quickly as possible.

THE PCF’S CRUCIAL ROLE The PCF exists for a single purpose: to drive research to IN DRIVING PROSTATE fi nd better treatments and a cure for recurrent prostate can- CANCER RESEARCH cer. In its fi rst 11 years, the PCF has raised more than $230 million, making it the world’s largest source of philanthropic support for prostate cancer research. By keeping its expenses low, the PCF has been able to devote 78 cents of every dollar raised to research, making it one of the most effi cient medi- cal charities in the country.

To date, the PCF has awarded grants to more than 1,200 researchers at more than 100 institutions worldwide. Last year, the PCF awarded grants to 25 researchers worldwide. Many of the proposals submitted were highly worthy of funding, yet were turned down simply due to lack of funds. The PCF is committed to working with its donors and partners to raise enough funds so that every worthy applicant receives funding. “ I cannot tell you what a difference the PCF has made in the lives of men and their families. After working in this fi eld for 45 years, I’m excited about what the future holds.” NAME Donald S. Coffey, Ph.D.

AGE 72

OCCUPATION Professor of urology, oncology, pharmacology and molecular sciences and pathology, The Johns Hopkins University School of Medicine

PCF CONNECTION The “grandfather” of prostate cancer research, Dr. Coffey was the fi rst scientist to join forces with the PCF and has been a strategic guide to the Foundation ever since.

“ For the fi rst time in my life, I honestly think we can cure prostate cancer. The PCF is largely responsible for that.”

14 Prostate Cancer Foundation

Prostate cancer also has the The PCF employs a novel “fast-track” approach to funding strongest familial link among scientifi c research. Rather than requiring applicants to spend all major cancers. Twenty- valuable time crafting elaborate funding requests only to have fi ve percent of prostate cancer them wait months for a decision, the PCF has greatly streamlined patients have a relative with the process, requiring only a fi ve-page application and providing the disease. Race is also a a response within 90 days. This approach has enabled the PCF factor—African Americans to bring prostate cancer research quickly up to speed and has are 65% more likely to develop resulted in numerous breakthrough research achievements. prostate cancer compared with Recent PCF achievements include: Caucasians, and are twice as likely to die from it. Groundbreaking work with recent Nobel Prize winner Aaron Ciechanover, M.D., D.Sc., for his work in illuminating the sig- nifi cance of the proteasome, a cellular function that regulates the destruction of unneeded cell proteins. Dr. Ciechanover has received multiple research grants from the PCF to study the application of his research to prostate cancer.

The proteasome is the target of Millennium’s Velcade (bortezomib), which is currently in clinical trials for the treat- ment of prostate cancer and has already been approved for the treatment of multiple myeloma. The PCF provided crucial early funding to support the initial development of Velcade.

Abbott Laboratories’ 2004 submission of an application to market Xinlay (atrasentan) for the treatment of metastatic hormone-refractory prostate cancer, an advanced stage of prostate cancer that no longer responds to hormone treatment and has spread to other parts of the body, particularly the bones.

The PCF provided initial funding for research at The Johns Hopkins University into atrasentan, an endothelin-1 receptor antagonist, which was proven to slow the growth of prostate cancer cells in the laboratory and in animal studies. Additional PCF-supported research showed that the agent attacks prostate cancer in bone, laying the foundation for the successful clini- cal trials that followed and Abbott’s application for permission to market the drug. “ The PCF is doing a great job at harnessing more of society’s resources to defeat this deadly disease. Safeway is proud to support the extraordinary work of the PCF.” NAME Steve Burd

AGE 55

OCCUPATION Chairman and CEO, Safeway Inc.

PCF CONNECTION Un der Steve’s leadership, Safeway has become a leader of community causes, including prostate cancer, breast cancer, hunger relief and education.

“ Prostate cancer is the most common cancer in America, attacking families in commu- nities everywhere. Since 2001, Safeway has raised more than $8 million for prostate cancer research, because our vision has always been to give back to the communities we serve.”

18 Prostate Cancer Foundation

Progress toward the improvement of clinical trials through the development of new clinical end points for studying the effectiveness of prostate cancer therapies. In 2004, the FDA convened the fi rst-ever workshop to consider new alternatives for measuring the effectiveness of potential prostate cancer drugs. Currently, most prostate cancer drugs require an increase in survival time to obtain FDA approval; it can take fi ve to ten years to gather enough evidence to support regulatory approval. Through the persistence of the PCF and many others, the FDA is now looking at alternatives such as “surrogate mark- ers” (information about changes in the body that are believed to provide insight into the progress or remission of prostate cancer) to predict the effi cacy of a new drug. One such highly promising surrogate marker, the observed change in PSA levels in men with prostate cancer, has been heavily studied with the support of the PCF. The PCF is continuing to work in concert with researchers and the FDA to identify new clinical end points and speed the drug development and approval process.

Each year, the PCF hosts a Issuance of the inaugural Report to the Nation on Prostate Scientifi c Retreat for more Cancer, a groundbreaking new source of leading-edge prostate than 350 leading prostate cancer information geared to healthcare professionals involved cancer research scientists, in the care of prostate cancer patients, including urologists, biopharmaceutical executives medical oncologists and radiation oncologists. The 96-page and government policy makers. Report, developed in conjunction with WebMD/Medscape, It is now the world’s leading the leading provider of online healthcare education, offers a annual scientifi c gathering comprehensive overview of the state of the art in prostate cancer focused on the prevention, diagnosis, treatment and prevention, and was authored by 24 of treatment and cure of the world’s leading experts on the subject. Chapters range from prostate cancer. detection and diagnosis to chemotherapeutic options, emerging therapies, nutrition and prevention strategies, and management of the side effects of prostate cancer therapy. The purpose of the Report is to supply clinicians with a clearer understanding of how to work together to provide optimal care to patients with prostate cancer. “ There’s nobody else, no other entity in the world, that matches the PCF’s dedication and creativity in raising money and fi nding cures.” NAME Wade F. B. Thompson

AGE 64

OCCUPATION Chairman, President and CEO, Thor Industries, Inc.

PCF CONNECTION A key PCF supporter and a survivor of prostate cancer, melanoma and colon cancer, Wade is dedicating his life to defeating cancer.

“ Despite exercise, a good diet and annual medical checkups, prostate cancer can strike anybody, at any time. We all should be thankful to the PCF for the progress they have made towards fi nding a cure.”

22 Prostate Cancer Foundation

The PCF, with the support of its Pharmaceutical Industry Roundtable, distributed more than 17,000 copies to treating physicians around the U.S. and has made it available for free online. The WebMD/Medscape Web site tracked more than 45,000 unique visits to the Report in just over four months. In addition, over 4,000 Continuing Medical Education (CME) credits have been issued.

THE COLLABORATIVE We can’t do it alone. It’s as simple as that. To beat prostate EFFORT: BUILDING cancer once and for all, the PCF must leverage the talents BRIDGES TO BEAT PROSTATE CANCER and resources of thousands of people and institutions around the world. Collaboration, cooperation and teamwork have been hallmarks of the PCF from the start, and they remain important components of the PCF’s ongoing strategy.

Examples of the PCF’s recent collaborative efforts include:

Annual Scientifi c Retreat: Each year, the PCF hosts a Scientifi c Retreat for more than 350 leading prostate cancer research scientists, biopharmaceutical executives and government policy makers. It is now the world’s leading annual scientifi c gathering focused on the prevention, treatment and cure of prostate cancer.

The retreat features three days of scientifi c presentations, poster sessions and intense dialogue about clinical data, new discoveries, emerging treatment strategies and policies to accelerate drug discovery and development.

The PCF, with the support of The PCF’s 11th Annual Retreat, held in October 2004 in Lake its Pharmaceutical Industry Tahoe, Nevada, featured many noteworthy presentations, Roundtable, distributed more including several involving the nutritional aspects of prostate than 17,000 copies of the cancer prevention and treatment. Meir Stampfer, M.D., of the Report to the Nation on Harvard School of Public Health, presented preliminary fi nd- Prostate Cancer. ings of a study currently underway, noting that when men with a particular genotype had an increased intake of antioxidants, they reduced their risk of prostate cancer to 50% below that of “ My father was diagnosed with prostate cancer in 1996. We were devastated as a family and scared. We knew this was not just a disease for men but for everyone in the family.” NAME Beth Kobliner Shaw

AGE 40

OCCUPATION Financial journalist, author of Get a Financial Life: Personal Finance in Your Twenties and Thirties and the founder of Kobliner.com.

PCF CONNECTION Af ter the diagnosis of her father, Beth was instrumental in bringing about a 25-fold increase in government funding, ensuring the advancement of prostate cancer research.

“ Finding the PCF was like fi nding an oasis. They’re wonderful people who knew what we were going through—they helped us tackle one of the most diffi cult situations.”

26 Prostate Cancer Foundation

June M. Chan, Sc.D., of the the rest of the population; when they took beta-carotene supple- University of California at ments, they were nearly 60% less likely to die from prostate San Francisco, presented cancer. Because an estimated 25% of the population has this data gleaned from the Health genotype, these fi ndings can have far-reaching effects. Professionals Follow-Up Further, June M. Chan, Sc.D., of the University of California at Study showing that increased San Francisco, presented data gleaned from the Health Profes- consumption of lycopene sionals Follow-Up Study showing that increased consumption can reduce the risk of disease of lycopene can reduce the risk of disease progression in men progression in men who have who have already been diagnosed with prostate cancer. Among already been diagnosed with men followed by the study, those who consumed an extra two prostate cancer. servings per week of lycopene-rich cooked tomato products after prostate cancer diagnosis reduced their risk of disease progression by nearly 20%.

Clinical Research Consortium: Eight leading cancer research centers are collaborating under the auspices of the PCF to test and develop promising prostate cancer therapies. By agreeing to eliminate institutional barriers and to conduct fast-track clinical testing, the consortium provides the pharmaceutical industry with an ideal platform for speeding prostate cancer drugs to market. The eight member institutions are Cedars- Sinai Medical Center (Los Angeles); Dana-Farber Cancer Institute (Boston); The Johns Hopkins University (Baltimore); M.D. Anderson Cancer Center (Houston); Memorial Sloan- Kettering Cancer Center (New York); the UCSF Comprehensive Cancer Center (San Francisco); the University of Michigan Medical Center (Ann Arbor); and the University of Wisconsin Comprehensive Cancer Center (Madison).

Pharmaceutical Industry Roundtable: The world’s leading pharmaceutical companies play a crucial role in beating prostate cancer. To engage them most effi ciently and usefully, the PCF has formed an Industry Roundtable designed to reduce barri- ers to the optimal treatment of prostate cancer; promote and conduct prostate cancer research; advocate for accelerated drug “ By supporting the PCF, you have joined the fi ght of your life — we must and can win!” NAME Aaron Ciechanover, M.D., D.Sc.

AGE 58

OCCUPATION Pr ofessor, Vascular and Tumor Biology Research Center; Director, The Rappa- port Faculty of Medicine and Research Institute, Technion, Israel Institute of Technology

PCF CONNECTION Si nce 2000, the PCF has funded Dr. Ciechanover through its Israel Initiative. In 2004, he received a Nobel Prize for his work on the signifi cance of the proteasome, which regulates the destruction of unneeded cell proteins.

30 Prostate Cancer Foundation

approvals; and support the development of assertive treatment guidelines and interdisciplinary medical education. Formed in 2004, the charter members of the Roundtable are Abbott Laboratories, Bristol-Myers Squibb, Novartis and Sanofi -Aventis. The Roundtable’s fi rst major achievement was the publication and distribution of the Report to the Nation on Prostate Cancer in 2004.

THE PCF’S YEAR-ROUND The PCF is grateful for the wide-ranging support it receives FUND-RAISING EFFORTS for its work to beat prostate cancer. Each year, thousands of people give generously of their time and money to support the PCF’s relentless efforts to fi nd better treatments and a cure for recurrent prostate cancer.

Even with all that help, it’s still not enough. The PCF is unable to fund all of the outstanding grant requests it receives and must turn down researchers eager to probe the complexities of prostate cancer and develop innovative new treatments. Every day, the PCF reaches out to new individuals and organizations to join the fi ght.

The PCF has formed an In 2004, the PCF was pleased to welcome the following new Industry Roundtable designed supporters to the team: to reduce barriers to the optimal Callaway Golf: In September, Callaway sponsored a “Million treatment of prostate cancer; Dollar Putt” contest outside the New York Stock Exchange. As promote and conduct prostate hundreds of people watched on the street, celebrities competed cancer research; advocate for to sink a 100-foot putt, with the proceeds going to the PCF. accelerated drug approvals; and support the development eBay: Over the summer of 2004, eBay hosted “Because You of assertive treatment guide- Love Him,” an online auction of more than 350 items, including lines and interdisciplinary one-of-a-kind offerings such as two hours with Magic Johnson; medical education. an afternoon with Arnold Palmer; dinner with Jennifer Hawkins, Miss Universe 2004; lunch with platinum recording artist Avril Lavigne; tennis with Donald Trump; and a visit to the set of the hit TV show Las Vegas with James Caan. The auction raised more than $200,000 for prostate cancer research and will become an annual event. “ The PCF has been a driving force in expanding and accelerating prostate cancer research. The PCF’s research and focus on diet is very important. I’m convinced of that!” NAME Nelson Peltz

AGE 62

OCCUPATION Chairman and CEO, Triarc Companies, Inc.

PCF CONNECTION A leader in the business community and a recognized philanthropist, Nelson has brought his considerable skills to the PCF board of directors.

“ The number and caliber of research scientists dedicated to prostate cancer has increased dramatically over the last 12 years. I credit that primarily to the PCF.”

34 Prostate Cancer Foundation

Safeway, the food and drug Esquire: This leading men’s magazine has selected the PCF as retailer, raised $3.3 million its offi cial charity. It is supporting the cause through a prostate for prostate cancer research cancer advertorial and by encouraging leading men’s fashion in 2004 through point-of- companies and retailers to support prostate cancer research. purchase promotions at more GNC: In June, this leading specialty retailer of vitamin, than 15,000 checkout stands mineral, herbal and sports nutrition supplements joined the in all 1,600 Safeway stores fi ght against prostate cancer with in-store promotions and in the U.S. fund-raising, blue-ribbon prostate cancer awareness pins and employee incentives to raise money for prostate cancer research at its more than 5,000 retail outlets throughout the U.S.

Hugo Boss: This maker of fi ne men’s and women’s clothing hosted two special in-store “True-Blue Night” events in New York City and Beverly Hills, with a portion of the proceeds going to benefi t the PCF. In addition, during the months of June and September in honor of Father’s Day and Prostate Cancer Awareness Month, respectively, Hugo Boss donated a percentage of sales to the PCF.

Ferragamo: As a participant in the “Blue for Men” campaign, legendary fashion purveyor Ferragamo donated 15% of select blue tie purchases during the month of September to the PCF.

The Prostate Cancer Foundation wouldn’t be where it is today—the world’s leading source of philanthropic support for prostate cancer research—without its longtime supporters. Highlights of their efforts in 2004 included:

A Night to Remember: The Niebaum-Coppola Estate Winery in Napa hosted Marvin Shanken’s 12th annual fund-raiser for the PCF, raising nearly $800,000 for prostate cancer research.

Safeway: The food and drug retailer raised $3.3 million for prostate cancer research in 2004 through point-of-purchase promotions at more than 15,000 checkout stands in all 1,600 Safeway stores in the U.S. Employees also participated in internal fund-raising drives to boost proceeds. “ I learned about the PCF after doing a great deal of research and investigation. I decided this was the one charity where I wanted to consolidate all my energy and time.” NAME Marvin R. Shanken

AGE 62

OCCUPATION Chairman, M. Shanken Communications Inc.

PCF CONNECTION Ma rvin created and produces the annual event, A Night to Remember, which in 2004 raised more than $800,000 for prostate cancer research. Since inception, Marvin’s events have raised more than $4 million for the PCF.

“ Prostate cancer is perhaps the most serious disease facing all men. And, as a man and publisher of men’s magazines, this subject is near and dear to my heart, which is why I support and tell all my friends to support the PCF.”

38 Prostate Cancer Foundation

Major League Baseball: Once again, baseball went to bat for prostate cancer research during the Home Run Challenge over Father’s Day. Everyone from groundskeepers to team owners donned blue wristbands and watched as sluggers belted 132 home runs during the fund-raising week, generating $2 million to support the work of the PCF.

Benefi t at Bighorn Pro-Am: Founded in 1998 with the help of pro golfer Jim Colbert after he was diagnosed with prostate cancer, this pro-am tournament joins current players on the Champions Tour with PCF supporters for a day on one of the country’s premier golf courses, in Palm Desert, California. Pro golfers who have participated at Bighorn include Bruce Fleisher, Hale Irwin, Gary McCord, Jim Thorpe, Jay Siegel and Lee Trevino.

Carl H. Lindner Pro-Am Invitational Tennis Tournament: Hosted by Donald Trump at his legendary Mar-a-Lago Club in Palm Beach, Florida, this round-robin tennis tournament and fund-raiser draws a star-studded fi eld, including tennis pros such as Chris Evert, Jimmy Connors, Mats Wilander, Cliff Drysdale, Petr Korda, Stan Smith and Fred Stolle.

Everyone from groundskeepers Indian Wells Tennis Tournament: Held in conjunction with to team owners donned blue the Pacifi c Life Open, this round-robin tennis tournament pairs wristbands and watched as amateurs and celebrities with some of the best players in tennis. sluggers belted 132 home runs Pros Luke and Murphy Jensen, John Lloyd, Jeff Tarango, Jonas during the fund-raising week, Bjorkman and Eddie Dibbs have taken part in this benefi t for generating $2 million to sup- the PCF. port the work of the PCF. Gourmet Games: Blending the PCF’s advocacy of a cancer- fi ghting diet with fund-raising, the PCF hosts “Gourmet Games” in Los Angeles and Seattle, featuring both wine and food tastings and contests between teams of celebrities and VIPs, challenging participants’ tastes and perceptions of food in a fun and informative evening. “ The PCF is a fi rst-class organi- zation that gives people hope. They are real people who are helping provide answers and a cure for a disease that affects men everywhere.” NAME Rosey Grier

AGE 72

OCCUPATION Former NFL Star, New York Giants and Los Angeles Rams

PCF CONNECTION A member of the PCF board of directors, Rosey has been a strong supporter from the beginning, working hard to create awareness of prostate cancer throughout African American communities.

“As bad as this disease is for Caucasians, it’s much worse for African Americans. But don’t give up, the PCF is bringing everyone together to fi nd a cure in our lifetimes.”

42 42 Prostate Cancer Foundation

RESEARCH AWARDS California Institute of Technology Cornell University $450,000 $4,100,000 Albert Einstein Raymond J. Deshaies, Ph.D. Beatrice S. Knudsen, M.D., Ph.D. College of Medicine Huatao Guo, Ph.D. David M. Nanus, M.D. $75,000 Alexander J. Varshavsky, Ph.D. New York Presbyterian Hospital Nicole B. Schreiber-Agus, Ph.D. Neil H. Bander, M.D. California Pacifi c Medical Center Assaf Harofe Medical $100,000 Dartmouth-Hitchcock Center (Israel) Robert J. Debs, M.D. Medical Center $150,000 $75,000 Amnon Zisman, M.D. Cancer Institute of New Jersey Marc S. Ernstoff, M.D. $75,000 Bar-Ilan University (Israel) Robert S. DiPaola, M.D. Duke University $225,000 $1,050,000 Shlomo Grossman, Ph.D. Cantonal Hospital St. Gall Phillip Febbo, M.D. Uri Nir, Ph.D. (Switzerland) Eli Gilboa, Ph.D. $75,000 Susan Halabi, Ph.D. Baylor University Marcus Groettrup, Ph.D. Michael C. Pirrung, Ph.D. $3,300,000 David T. Price, M.D. Jacques Banchereau, Ph.D. Case Western Reserve University Johannes W. Vieweg, M.D. $350,000 Baylor College of Medicine Sanford Markowitz, M.D., Ph.D. Norman M. Greenberg, Ph.D. Eastern Virginia Medical School Bingcheng Wang, Ph.D. Dov Kadmon, M.D. $175,000 Paula Kaplan-Lefko, Ph.D. George L. Wright Jr., Ph.D. Cedars-Sinai Medical Center Michael Kattan, Ph.D. $2,095,000 Dolores J. Lamb, Ph.D. Emory University David B. Agus, M.D. Bert W. O’Malley, M.D. $250,000 H. Phillip Koeffl er, M.D. David R. Rowley, Ph.D. Wayne Harris, M.D. Isett Laux, Ph.D. Peter T. Scardino, M.D. John A. Petros, M.D. Timothy C. Thompson, Ph.D. Cleveland Clinic Foundation Ming-Jer Tsai, Ph.D. Erasmus University $150,000 Nancy L. Weigel, Ph.D. (Netherlands) Katerina Gurova, Ph.D. $250,000 Edward Plow, Ph.D. Ben-Gurion University Jan Trapman, Ph.D. of the Negev (Israel) Gert J. van Steenbrugge, Ph.D. Cold Spring Harbor Laboratory $375,000 $100,000 Ron N. Apte, Ph.D. Fred C. Hutchinson Cancer Robert Lucito, Ph.D. Joseph Levy, Ph.D. Research Center Angel Porgador, Ph.D. $2,680,000 Columbia University Shraga Segal, Ph.D. Peter S. Nelson, M.D. $2,129,500 Elaine A. Ostrander, Ph.D. Brandeis University Allen Pavilion Presbyterian Hospital Janet L. Stanford, Ph.D. $250,000 Carl A. Olsson, M.D. Lizbeth Hedstrom, Ph.D. Atchley Pavilion Georgetown University Gregory A. Petsko, Ph.D. Ralph Buttyan, Ph.D. $1,000,000 College of Physicians and Surgeons Lombardi Cancer Center Burnham Institute Paul B. Fisher, Ph.D. Edward P. Gelmann, M.D. $1,786,000 Aaron E. Katz, M.D. Robert L. Martuza, M.D. Wadih Arap, M.D., Ph.D. Nickolas Papadopoulos, Ph.D. Renxiao Wang, Ph.D. Nuria E. Assa-Munt, Ph.D. Shaomeng Wang, Ph.D. Kathryn R. Ely, Ph.D. Columbia Presbyterian Medical Center John C. Reed, M.D., Ph.D. Daniel Petrylak, M.D. Erkki I Ruoslahti, M.D., Ph.D. 43

Hadassah University (Israel) Harvard School of Public Health Karolinska Institute (Sweden) $485,000 June M. Chan, Sc.D. $75,000 Rachel Bar-Shavit, Ph.D. Edward Giovannucci, M.D. Hans-Olov Adami, M.D., Ph.D. Eithan Galun, M.D., Ph.D. Laurie H. Glimcher, M.D. Amnon Peled, Ph.D. Meir Stampfer, M.D., Sc.D. Klinikum de Justus-Liebig Eli Pikarsky, M.D., Ph.D. Dimitrios Trichopoulos, M.D. Universitat Giessen (Germany) Israel Vlodavsky, Ph.D. Massachusetts General Hospital $175,000 Joel Finkelstein, M.D. Trinad Chakraborty Harvard University Robert L. Martuza, M.D. $11,275,000 Matthew R. Smith, M.D., Ph.D. La Jolla Institute for Beth Israel Deaconess Ching-Hsuan Tung, Ph.D. Allergy and Immunology Medical Center Anthony L. Zietman, M.D. $75,000 Lewis C. Cantley, Ph.D. Stephen Schoenberger, Ph.D. John V. Fragioni, M.D., Ph.D. Hebrew University (Israel) Sandra M. Gaston, Ph.D. $800,000 Long Island College Hospital Richard Junghans, M.D., Ph.D. Yinon Ben-Neriah, M.D., Ph.D. $15,000 Tow ia A. Libermann, Ph.D. Howard Cedar, M.D., Ph.D. Ivan Grunberger, M.D. Massimo Loda, M.D. Eli Keshet, Ph.D. Jan E. Schnitzer, M.D. Alexander Levitzki, Ph.D. Loyola University David Naor, Ph.D. Medical Center Brigham and Women’s Hospital $200,000 Anthony V. D’Amico, M.D., Ph.D. Eugene D. Kwon, M.D. Phillip Febbo, M.D. Indiana University $200,000 James W. Fett, Ph.D. McGill University Joshua LaBaer, M.D., Ph.D. Thomas A. Gardner, M.D. George W. Sledge, M.D. $75,000 Kevin R. Loughlin, M.D. Nahum Sonenberg, Ph.D. Karen A. Olson, Ph.D. Jeffrey L. Sklar, M.D., Ph.D. Institute for Systems Biology $500,000 Massachusetts Institute Children’s Hospital Leroy E. Hood, M.D., Ph.D. of Technology Judah Folkman, M.D. $1,535,000 Michael Klagsburn, Ph.D. John Wayne Cancer Institute Sandra M. Gaston, Ph.D. Calvin J. Kuo, M.D. $50,000 Richard O. Hynes, Ph.D. Marsha A. Moses, Ph.D. Frederick R. Singer, M.D. Jun Liu, Ph.D. Richard C. Mulligan, Ph.D. Peter H. Seeberger, Ph.D. Bruce R. Zetter, Ph.D. Johns Hopkins University Ganesh Venkataraman, Ph.D. Dana-Farber Cancer Institute $13,697,000 Whitehead Institute for Ranaan Berger, M.D., Ph.D. Philip A. Beachy, Ph.D. Biomedical Research Myles A. Brown, M.D. David Berman, M.D., Ph.D. John M. Essigmann, Ph.D. Harvey Cantor, M.D. G. Steven Bova, M.D. Eric S. Lander, Ph.D. Diego Castrillon, M.D., Ph.D. Michael A. Carducci, M.D. Richard C. Mulligan, Ph.D. Lan Bo Chen, Ph.D. Angelo DeMarzo, M.D., Ph.D. Glenn Dranoff, M.D. Samuel R. Denmeade, M.D. Phillip Febbo, M.D. Mario Eisenberger, M.D. Daniel J. George, M.D. Stephen J. Freedland, M.D. William C. Hahn, M.D., Ph.D. John T. Isaacs, Ph.D. Philip W. Kantoff, M.D. William B. Isaacs, Ph.D. David M. Livingston, M.D. Clara L. Kielkopf, Ph.D. Massimo Loda, M.D. Hyam I. Levitsky, M.D. Thomas Roberts, Ph.D. Joel B. Nelson, M.D. William R. Sellers, M.D. William G. Nelson, M.D., Ph.D. Sabina Signoretti, M.D. Alan W. Partin, M.D., Ph.D. Bruce M. Spiegelman, Ph.D. Roberto Pili, M.D. Robert H. Vonderheide, M.D., Ronald Rodriguez, M.D., Ph.D. D.Phil. Jonathan W. Simons, M.D. Patrick C. Walsh, M.D. 44 44 Prostate Cancer Foundation

Mayo Clinic and Foundation New York Medical College Salk Institute for $500,000 $150,000 Biological Studies Lorraine A. Fitzpatrick, M.D. Cancer Research Institute $760,050 John C. Morris, M.D. Sophie Chen, Ph.D. Ronald M. Evans, Ph.D. Donald J. Tindall, Ph.D. New York University San Diego Cancer Research Memorial Sloan-Kettering $430,000 $75,000 Cancer Center Maarten C. Bosland, D.V.Sc., Ph.D. R. Michael Williams, M.D., Ph.D. $14,535,000 Herbert Lepor, M.D. David B. Agus, M.D. Ian J. Mohr, Ph.D. Scripps Research Institute William R. Fair, M.D., F.A.C.S. Samir Taneja, M.D. $975,000 George Farmer, Ph.D. Ruben A. Abagyan, Ph.D. Leonard P. Freedman, Ph.D. Skirball Institute of K.C. Nicolaou, Ph.D. Zvi Fuks, M.D. Biomolecular Medicine Prabhakar Tripuraneni, M.D. Polly Gregor, Ph.D. Ruben Abagyan, Ph.D. Adriana Haimovitz-Friedman, Ph.D. Sheba Medical Center (Israel) Warren D.W. Heston, Ph.D. Northwest Hospital $150,000 William Kevin Kelly, M.D. $475,000 Gideon Rechavi, M.D., Ph.D. Philip O. Livingston, M.D. Gerald P. Murphy, M.D., D.Sc. Paul A. Marks, M.D. Stanford University Michael R. McDevitt, Ph.D. Northwestern University $1,225,000 David Nanus, M.D. $200,000 Gerald R. Crabtree, M.D. Neal Rosen, M.D., Ph.D. Wade Bushman, M.D., Ph.D. David Feldman, M.D. Michael Sadelain, M.D., Ph.D. Zhou Wang, Ph.D. Calvin J. Kuo, M.D. Peter T. Scardino, M.D. John E. McNeal, M.D. David A. Scheinberg, M.D., Ph.D. Ohio State University Donna M. Peehl, Ph.D. Howard I. Scher, M.D. $100,000 Thomas A. Stamey, M.D. George Sgouros, Ph.D. M. Guill Wientjes, Ph.D. David Shaffer, M.D., Ph.D. St. Louis University Moshe Shike, M.D. Oregon Health Sciences University $75,000 Susan F. Slovin, M.D., Ph.D. $100,000 William S.M. Wold, Ph.D. Peter Smith-Jones, Ph.D. Ron G. Rosenfeld, M.D. Jedd D. Wolchok, M.D., Ph.D. State University of New York Preventive Medicine $112,500 Menzies Centre for Population Research Institute $500,000 Downstate Medical School Health Research (Australia) Jack Mydlo, M.D. $50,000 Dean Ornish, M.D. David A. Mackey, M.D. Stony Brook Rabin Medical Center (Israel) Victor I. Romanov, Ph.D. Mount Sinai School of Medicine $50,000 $275,000 Avishay Sella, M.D. Technion, Israel Institute of Michael J. Droller, M.D. Technology (Israel) Irwin H. Gelman, Ph.D. Rockefeller University $625,000 John A. Martignetti, M.D., Ph.D. $500,000 Ami Aronheim, Ph.D. Robert G. Roeder, Ph.D. Aaron Ciechanover, M.D., D.Sc. Strang Cancer Research Laboratory Fuad Fares, D.Sc. Martin Lipkin, M.D. Ehud Keinan, Ph.D. Gera Neufeld, Ph.D. Roger Williams Medical Center Israel Vlodavsky, Ph.D. $100,000 Richard P. Junghans, Ph.D., M.D. 45

Tel-Aviv University (Israel) University of California University of California, San Francisco $400,000 $16,465,068 Jeffrey Arbeit, M.D. Zvi Fishelson, Ph.D. Lawrence Livermore Allan Balmain, Ph.D. Sara Lavi, Ph.D. National Laboratory Elizabeth Blackburn, Ph.D. Ada Rephaeli, Ph.D. Christine Hartmann Siantar, Ph.D. Peter R. Carroll, M.D. Ilan Tsarfaty, Ph.D. June Chan, Sc.D. University of California, Berkeley Sourasky Medical Center Colin Collins, Ph.D. James P. Allison, Ph.D. Marc Diamond, M.D. Ben-Zion Katz, Ph.D. Carolyn Bertozzi, Ph.D. Avi Orr-Urtreger, M.D., Ph.D. Robert Fletterick, Ph.D. Arthur A. Hurwitz, Ph.D. Mark W. Frohlich, M.D. David H. Raulet, Ph.D., B.S. Thomas Jefferson University Rodney Guy, Ph.D. Peter G. Schultz, Ph.D. Douglas Hanahan, Ph.D. $125,000 David E. Wemmer, Ph.D. Michael J. Mastrangelo, M.D. Ronald H. Jensen, Ph.D. Albert J. Wong, M.D. University of California, Davis John Kurhanewicz, Ph.D. Shing-Jien Kung, Ph.D. James D. Marks, M.D., Ph.D. Tulane University University of California, Dean Ornish, M.D. $500,000 Los Angeles Mack Roach III, M.D. Andrew V. Schally, M.D., Ph.D. Arie S. Belldegrun, M.D. Eric J. Small, M.D. Michael F. Carey, Ph.D. Thea Tlsty, Ph.D. University Hospital, Nijmegen Rowan T. Chlebowski, M.D., Ph.D. University of California, (Netherlands) Pinchas Cohen, M.D. Santa Barbara $275,000 Jean B. deKernion, M.D. Dulal Panda, Ph.D. Marion J.G. Bussemakers, Ph.D. Purnima Dubey, Ph.D. Sanjiv S. Gambhir, M.D., Ph.D. University of Chicago University of Alabama, David Heber, M.D., Ph.D. $425,000 Birmingham Harvey R. Herschman, Ph.D. Douglas K. Bishop, Ph.D. $100,000 Michael E. Jung, Ph.D. Carrie W. Rinker-Schaeffer, Ph.D. David T. Curiel, M.D. Jay R. Lieberman, M.D. Mitchell H. Sokoloff, M.D. Carl W. Miller, Ph.D. Ben May Institute for University of Arizona Ayyappan K. Rajasekaran, Ph.D. Cancer Research $150,000 Robert Reiter, M.D. Shutsung Liao, Ph.D. Leslie Gunatilaka, Ph.D., B.S. Peter Rosen, M.D. Mark W. Kunkel, Ph.D. Kathleen M. Sakamoto, M.D. University of Colorado Charles L. Sawyers, M.D $730,000 University of Basel Marc A. Seltzer, M.D. L. Michael Glode, M.D. (Switzerland) Ke Shuai, Ph.D. William E. Huffer, M.D. $75,000 Peter Tontonoz, M.D., Ph.D. Andrew S. Kraft, M.D. Lukas Bubendorf, M.D. Owen N. Witte, M.D. Gary J. Miller, M.D., Ph.D. Hong Wu, M.D., Ph.D. University of Bern University of California, San Diego University of Connecticut (Switzerland) Dennis A. Carson, M.D. $100,000 $100,000 Randolph D. Christen, M.D. Pramod Srivastava, Ph.D. George N. Thalmann, M.D. Lawrence S.B. Goldstein, Ph.D. Michael Karin, Ph.D. University of Edinburgh University of British Columbia Michael G. Rosenfeld, Ph.D. (Scotland) $100,000 Helen P. Tighe, Ph.D. $75,000 Martin Gleave, M.D. Maurizio Zanetti, M.D. Fouad K. Habib, Ph.D. 46 46 Prostate Cancer Foundation

University of Helsinki (Finland) University of North Carolina, M.D. Anderson Cancer Center $200,000 Chapel Hill Wadih Arap, M.D., Ph.D. Institute of Biomedicine $250,000 Danai Daliani, M.D. Olli A. Janne, M.D., Ph.D. David Ornstein, M.D. John DiGiovanni, Ph.D. Terry Van Dyke, Ph.D. Isaiah J. Fidler, D.V.M., Ph.D. University of Illinois Sue-Hwa Lin, Ph.D. $50,000 University of Pennsylvania Christopher J. Logothetis, M.D. Nissum Hay, Ph.D. $400,000 David J. McConkey, Ph.D. Mark I. Greene, M.D., Ph.D. Timothy J. McDonnell, M.D., Ph.D. University of Innsbruck Wistar Institute Nora M. Navone, M.D., Ph.D. (Austria) George C. Prendergast, Ph.D. Christos N. Papandreou, M.D., Ph.D. $100,000 Renata Pasqualini, Ph.D. Zoran Culig, M.D. University of Pittsburgh Dean G. Tang, M.D., Ph.D. $2,275,000 Andrew C. von Eschenbach, M.D. University of Iowa Michael J. Becich, M.D., Ph.D. Christopher G. Wood, M.D. $75,000 Barbara A. Foster, Ph.D. Southwestern Medical Center, Dallas George Weiner, M.D. John Gilbertson, M.D. Jerry W. Shay, Ph.D. Susan L. Greenspan, M.D. University of Kentucky Candace S. Johnson, Ph.D. University of Toronto (Canada) $100,000 Joel B. Nelson, M.D. $350,000 Vivek M. Rangnekar, Ph.D. Donald L. Trump, M.D. Sunnybrook Health Science Center Janey Whalen, Ph.D. Shoukat Dedhar, Ph.D. University of Maryland Robert S. Kerbel, Ph.D. $200,000 University of Rochester Natasha Kyprianou, Ph.D. $400,000 University of Utah, Yun Qiu, Ph.D. Chawnshang Chang, Ph.D. Health Sciences Center Edward Messing, M.D. $100,000 University of Massachusetts Arthur R. Brothman, Ph.D. $325,000 University of Southern Michael R. Green, M.D., Ph.D. California University of Virginia Shuk-Mei Ho, Ph.D. $200,000 $3,825,000 Mani Menon, M.D. Gerhard A. Coetzee, Ph.D. Leland W.K. Chung, Ph.D. Donald G. Skinner, M.D. Thomas A. Gardner, M.D. University of Michigan Theresa Guise, M.D. $3,275,000 University of Tampere (Finland) Deborah Lannigan, Ph.D. Arul M. Chinnaiyan, M.D., Ph.D. $300,000 Charles E. Myers Jr., M.D. Mark Day, Ph.D. Tapio Visakorpi, M.D., Ph.D. J. Thomas Parsons, Ph.D. Evan T. Keller, D.V.M., Ph.D. Fraydoon Rastinejad, Ph.D. Donna Livant, Ph.D. University of Tennessee Mitchell Sokoloff, M.D. Kenneth J. Pienta, M.D. $150,000 Michael J. Weber, Ph.D. Martin G. Sanda, M.D. Jeffrey Gingrich, M.D. Shaomeng Wang, Ph.D. University of Washington University of Texas $7,873,220 University of Missouri, Columbia $11,342,000 Arthur Camerman, Ph.D. $75,000 Health Science Center at San Antonio Martin A. Cheever, M.D. Valeri V. Mossine, Ph.D. Susan Padalecki, Ph.D. Leroy Hood, M.D., Ph.D. Gail Jarvik, M.D., Ph.D. University of Munich (Germany) Paul H. Lange, M.D. $100,000 Alvin Liu, Ph.D. Bernd Gansbacher, M.D. Robert L. Vessella, Ph.D.

University of Nebraska $100,000 Ming-Fong Lin, Ph.D. 47

University of Wisconsin Wayne State University $4,175,000 $350,000 David A. Boothman, Ph.D. Michael L. Cher, M.D. Chawnshang Chang, Ph.D. Keneth V. Honn, Ph.D. David F. Jarrard, M.D. Harper Hospital Douglas G. McNeel, M.D., Ph.D. J. Edson Pontes, M.D. George Wilding, M.D. Donald T. Witiak, Ph.D. Weizmann Institute of Science (Israel) Urological Sciences $1,625,000 Research Foundation Avri Ben-Ze’ev, Ph.D. $100,000 Hadassa Degani, Ph.D. Leonard S. Marks, M.D. Zelig Eshhar, Ph.D. Benjamin Geiger, Ph.D. Utah State Cancer Registry Yitzhak Koch, Ph.D. $183,420 Yoram Salomon, Ph.D. Janet Stanford, M.D. Rony Seger, Ph.D. Yechiel Shai, Ph.D. Vanderbilt University Yosef Shaul, Ph.D. $350,000 David Wallach, Ph.D. Sam Chang, M.D. Yosef Yarden, Ph.D. Robert Matusik, Ph.D. Yehiel Zick, Ph.D. Joseph A. Smith Jr., M.D. Yale University Veterans Administration $200,000 $4,622 Craig M. Crews, Ph.D. Patricia Cornett, M.D.

Volcani Center (Israel) $180,000 Mark Pines, Ph.D.

Vrije Universiteit medisch centrum (Netherlands) $100,000 Tanja D. de Gruijl, Ph.D.

Walter Reed Army Medical Center $50,000 David G. McLeod, M.D., J.D.

Washington University $3,439,166 William J. Catalona, M.D. Mark L. Day, Ph.D. Helen Donis-Keller, Ph.D. Steven F. Dowdy, Ph.D. Peter A. Humphrey, M.D., Ph.D. Jeffrey Milbrandt, M.D., Ph.D. Nobuyuki Oyama, M.D., Ph.D. Timothy L. Ratliff, Ph.D. Brian K. Suarez, Ph.D. 48 48Prostate Prostate Cancer Cancer Foundation Foundation

2004 DONOR LIST The Prostate Cancer Foundation would like to thank everyone who has donated to the foundation. We gratefully acknowledge the following individuals, foundations, corporations and others who have given at least $5,000 between our inception, in 1993, and December 31, 2004.

Founder ($50 Million +) Julian H. Robertson, Jr. Patrons ($250,000 – $499,999) Milken Family Foundation William A. Schwartz Anonymous (1) M. Shanken, Chairman Robert K. Barth Founder’s circle M. Shanken Communications, Inc. Brian and Kathleen Bean ($2,000,000 – $49,999,999) Thomas Spiegel Stephen and Chantal Cloobeck Anonymous (1) Martin and Pamela Wygod David and Sheryll Harkins David Hamilton Koch Charitable Gift Fund Carl and Edyth Lindner Benefactors L. John Doerr Lowell and Sandy Milken ($500,000 – $999,999) David and Marsha Ederer Michael and Lori Milken Anonymous (3) F W McCarthy Foundation News Corporation Foundation Ronald W. Burkle Howard Gittis Stewart and Lynda Resnick Winston H. Chen, Ph.D. Phillip and Lyn Goldstein Safeway, Inc. Clifton S. Robbins Charitable Fund Barbara J. Greenspun Stephen and Elaine Wynn Edward P. Evans Foundation Heinz North America Lawrence J. Ellison Stephen and Tomisue Hilbert Leadership Circle Sue Gin Ray and Ghada Irani ($1,000,000 – $1,999,999) D. Wayne and Anne Gittinger Joy and Jerry Monkarsh Anonymous (5) Golfers Against Cancer Family Foundation Leon and Debra Black Kern Family Foundation Peter Karmanos, Jr. Jamie B. Coulter Rush Limbaugh Herb and Natalie Kohler The Craig and Susan McCaw Carol and Earle I. Mack C. Michael and Elizabeth Kojaian Foundation Charles and Ann Mathewson Lester and Sue Smith Foundation Charles F. Dolan Scott and Susan McNealy Richard Mejasich William L. Edwards Gordon E. Moore Melvin and Bren Simon Andrew S. Grove Richard and Ellen Sandler Charitable Foundation No.1 Sidney Kimmel Jane and Terry Semel Richard N. Merkin, M.D. Thomas H. and Ann Tenenbaum Lee Edward and Martha Snider Bruce and Jeannie Nordstrom The Lincy Foundation Stuart Subotnick Allen and Madeleine Paulson Kerry Packer Michael and Lynne Tarnopol The R.D. and Joan Dale Nelson and Claudia Peltz/ Ted and Dani Virtue Hubbard Foundation Triarc Companies, Inc. Stanley and Barbara Zax Gene and Marianne Salmon Ronald and Ellen Perelman Sandra and Lawrence Post PGA Tour Charities, Inc Family Foundation Lewis and Peg Ranieri Prostate Cancer Foundation 49 49

Mickey and Karen Shapiro Martin and Audrey Gruss Laurence and Billie Tisch David E. and Beth Kobliner Shaw Richard B. Handler Tom and Diane Tuft Paul and Elle Stephens Joseph W. Harch Varian Associates Inc. Warren and Jale Trepp Thomas O. Hicks Viacom International, Inc. Clyde and Vera Turner Hilton Hotels Corporation Wade F.B. Thompson Leslie L. Vadasz Leo Hindery, Jr. Charitable Foundation Robert and Angela Voss Jon and Karen Huntsman Leon M. Wagner Dennis and Phyllis Washington Carl and Gail Icahn Raul and Vicki Walters Gary and Karen Winnick Peter W. Janssen Wasserman, Comden, Casselman & The John F. Scarpa Foundation Pearson LLP Partners ($100,000 – $249,999) Joseph and Diane Steinberg 1992 Will and Jean Marie Weinstein Anonymous (1) Charitable Trust Thomas and Emily Weisel William and Donna Acquavella Mel and Terry Karmazin John F. Welch, Jr. Phillip and Nancy Anschutz David Karpol William and Phyllis Mack Ambassador George L. Argyros, Sr. Michael and Jena King Family Foundation Arnie’s Army Battles Prostate Cancer Kissick Family Foundation Sam and Helen Zell Chris and Tory Bagdasarian Knowledge Universe Selig Zises Robert and Donna Baldwin Robert A. Kotick Marc R. Benioff Howard and Mary Lester Associates ($50,000 – $99,999) Braman Family Foundation Solomon and Rosie Lew Anonymous (4) Bristol-Myers Squibb Company Peter B. Lewis Robert W. Adler Gary S. Broad The Lynn Aymar Family Foundation Edward C. Allred Bruce R. and Jolene M. McCaw Fund Leni and Peter May Eric J. Aronson John and Barbara Burns George A. Mealey Michael and Marlene Aufrecht August A. Busch IV Avram Miller Facundo L. Bacardi California State Council of Laborers S. Leslie and Barbara Misrock Roger Barnett Ely R. Callaway Kenneth and Julie Moelis Kathy and Frank Baxter Wayne Calloway Moore Family Foundation Erin and Douglas Becker The Carole & Robert Daly Marc and Jane Nathanson Samuel Belzberg Charitable Foundation Linden Nelson Marshall Bennett James and Patricia Cayne John and Sally Nordstrom Ken Berg Cendant Corporation Joel M. Pashcow Phyllis and Martin Berman Max and Katharine Chapman Sumner and Paula Redstone Frank and Carol Biondi, Jr. Concern Foundation Leonard and Louise Riggio BlackRock Financial Management, Inc. The David Geffen Foundation Lew Rothman Dan Blumenthal Thomas and Gun Denhart Marc J. and Carolyn Rowan Jerry Brassfi eld James and Kristin Dolan Lewis and Rachael Rudin Shann Brassfi eld Donaldson, Lufkin & Jenrette Larry W. Ruvo Gresham T. Brebach, Jr. Jeremy D. Eden Haim and Cheryl Saban CAO International, Inc. Eli & Edythe L. Broad Foundation salesforce.com Frank Caufi eld Don Engel San Francisco Giants Ray and Patti Chambers Ernst & Young, LLP Shoes for Crews Alfred and Kathryn Checchi William F. Farley Silent Partners, Inc. Marshall and Maureen Cogan Ferolito, Vultaggio & Sons Jeffrey and Lisa Silverman James H. Coleman Ralph and Cynthia Finerman David M. Solomon David and Janet Kline Fund M. Anthony and Anne Fisher Alex G. Spanos Michael D. Dingman The G. Chris Andersen Avy and Marcie Stein Dunwoody Senior Men’s Family Foundation Ernest E. Stempel Golf Association Richard and Phyllis Gelb Sterling Equities Robert and Tricia Earl Eric and Anne Gleacher The Stern Family Foundation Paul Fleming Thomas and Holly Gores Roger and Susan Stone Theodore J. Forstmann Orland S. Greene Marty Tenenbaum Michael Frey 50 50 Prostate Cancer Foundation

Jim L. Gagin The Picower Foundation Robert A. Belfer Gantcher Family Philanthropic Fund Pritzker Foundation Robert and Catherine Beyer Jeffrey Gargiulo and Valerie Boyd Martin and Patricia Raynes Art H. Bilger Arthur and Linda Gelb Richard S. Ressler Tony Borhani Henry and Arline Gluck Tony Ressler and Jami Gertz Denis A. Bovin Stanley and Ilene Gold Meshulam Riklis Coco Brown Jeremy P. Goldberg The Riordan Foundation Steven A. Burd John and Kathleen Gorman George R. Roberts Brian P. Burns William and Susan Gross The Rose Foundation The Cecile and Fred Bartman Allen and Debbie Grubman Andrew M. Rosenfi eld Foundation Norb Guziewicz Pat and John Rosenwald Celine Dion Foundation J. Ira and Nicki Harris Steven and Daryl Roth John Cohlan Alan and Vivien Hassenfeld The Sam and Sarah Grossinger Gregory G. Coleman Roy W. Howard Foundation Howard Cox James Hudson David and Janelle Shaffer Lester and Renee Crown The John R. & Inge P. Stafford Harvey L. Silbert, Esq. Edgar and Elissa Cullman Foundation Jeffrey and Helaine Silverstein Ian M. Cumming Joseph H. Kanter Foundation William E. and Tonia Donnelley Simon Davidoff of Geneva Matthew Kaplan Paul and Celia Sirotkin Robert and Kelly Day John Kelley Stuart M. Sloan Dendreon Corporation Melvyn N. Klein Eric and Susan Smidt Mark Donnelly Charles G. Koch Don Soffer Effi ciency Enterprises Timothy Koogle Southern California District Bruce Eichner Dewanto Kurniawan Council of Laborers Harvey P. Eisen Laborers’ International Union of Saul P. Steinberg Lewis M. Eisenberg North America Louis B. Susman Lawrence R. Elins Lamkin Corporation Swing for the Cure The Entertainment Kenneth and Linda Lay Allan R. Tessler Industry Foundation Robert Levin William H. Tilley Thomas J. Fazio Robert E. Linton Jeanette Trepp Cary Fields Ira A. Lipman Van Van Auken Steve Fink Major League Baseball Charity, Inc. Clark Van Nostrand Bill Finneran Michael Marek Alice Walton Alex Fisher Martin & Toni Sosnoff Foundation Cheng Ching Wang David N. Fleischer Joseph and Anne McCann Jerry and Jane Weintraub Peter E. Fleming, Jr. John E. McCaw Jim and Kim Williams Todd Follmer Robert A. Meister David Yandry Theo and Constance Folz Barry Meyer Don Yannias Fred C. Hutchinson Cancer Julie and Edward J. Minskoff Zapolin Transactional Ventures, Inc. Research Center Jay and Elaine Moorin, Alain and Iris Jim Freer Schreiber, and ProQuest Friends ($25,000 – $49,999) Robert Fremont Morongo Band of Mission Indians Anonymous (1) Jerry Friedman Native American Rights Fund Don Ackerman The Fritz and Adelaide Kauffman Movado Group, Inc. Norman E. Alexander Foundation, Inc. Angelo R. Mozilo Allchin Foundation Paul R. Garcia Ken Nees Altadis USA, Inc. Philip H. Geier, Jr. Jim Newman Arby’s Jay Geldmacher George and Sandra Norcross Roland E. Arnall Stephen A. Geppi Phil R. North Arthur J. Gallagher & Co. Richard and Marcia Goldberg Ruth Ornest AstraZeneca Bruce Goldstein Jon Otto Charles F. Baird, Jr. Edward and Cheryl Gordon Palermo Ravich Family Foundation Jude T. Barbera, M.D. Maureen V. Gorman Prostate Cancer Foundation 51 51

Greenbriar Golf Association Nancy C. and Jeffrey A. Marcus Stephen and Phyllis West Wayne and Janet Gretzky Foundation, Inc. Gary and Nina Wexler Kenneth B. Hamlet Joseph Neubauer Rick Wooley John J. Hannan Aviv Nevo Don Zacharia Reed L. Harman New York Mets Foundation, Inc. Ralph and Kay Hemingway John Nickoll Supporters John and Susan Hess Chris K. Olander ($10,000 – $24,999) Samuel J. Heyman Pierre and Pam Omidyar Anonymous (3) Charlie J. Horky Peter M. Sacerdote Foundation David and Kay Aaker Hugo Boss Fashions, Inc. John and Laura Pomerantz Paul Abecassis Charles and Barbara Hurwitz Mark Quigley S. Daniel Abraham Vincent Iorio Richard E. Rainwater Abramson Family Foundation, Inc. IRI Golf Management, LP Ramblewood Country Club Gary Abramson Steve and Ellen Jackson Robert and Beverly Cohen Joseph P. Adams, Jr. Stanley R. Jaffe Family Foundation Sheldon Adelson Jim Beam Brands Co. Bill R. Roberts Neale M. Albert, Esq. Richard and Deborah Justice Richard and Barbara Rosenberg Larry Alleto Stephen and Marina Kaufman Stan and Patti Rosenfeld Bruce Ambler Michael Klein Eric Rothfeld Lee W. Ang Henry R. Kravis Peter H. Rothschild Anthony & Jeanne Pritzker Benjamin V. Lambert Barry L. Rupp Family Foundation Bill Lane, Jr. Alvin and Marilyn Rush Judd Apatow Bennett and Jerri Lebow Richard and Margaret Santulli The Armin & Esther Hirsch The Leeds Family Foundation John H. Schnatter Foundation Steve Lehman Irving Schneider Michael F. Armstrong Joseph Rob Link Allen B. Schwartz Victor Asad Joe Lumarda Stephen A. Schwarzman Michael F. Ashby Susan E. Lynch Richard M. Seigel Mark and Debbie Attanasio Gene E. Lynn David and Fela Shapell Jerry Auerbach Donald and Hilda Lytton William Shaw Abraham Azoulay David S. Mack Mace and Jan Siegel Jeffrey C. and Lori Barbakow Fredric Mack David and Lynn Silfen Sol Barer Harvey Mackay Herb Simon Ron and Judy Baron Bernard L. Madoff Fred L. Smith David and Judy Oliver Bash Laurence H. Mandelbaum Jeff P. Smith F. Harlan Batrus Howard and Nancy Marks Brian Sonnenberg William P. Beatson, Jr. Stanley and Pamela Maron Fred and Sharon Stein Richard I. Beattie Robert and Joan Masterson Steinberg Family Fund, Inc. Warren Beatty and Annette Benning Harold Matzner James Stern Gary S. Becker Keith W. McCaw Barry S. Sternlicht Allen J. Beeber Michael McKeever Spencer Stokes William J. Bell Richard McKenzie, Jr. Burt and Mary Sugarman Eric L. Berg Dennis Mehiel Jim Tarlton Jeff Berg Merck and Co., Inc. Marc Utay Anthony Bergamo, Esq. Herman and Susan Merinoff Wendell C. Van Auken Daniel G. Bergstein Harold M. Messmer, Jr. Peter Vegso David Berkoski Millennium Pharmaceuticals, Inc. Michael and Laura Venerable Allen J. Bernstein Theodore N. Miller Linda J. Wachner Les and Sheri Biller Michael and Cheryl Minikes Charles J. Wagner Stanley Black James F. Moore Samuel Waksal Joni Hirsch Blackman Robert E. Morrow Vera Wang and Arthur Becker Harvey Blau Mark E. Mortimer Michael and Jill Weinstein Charles X. Block 52 52 Prostate Cancer Foundation

Dennis Block J. Morton Davis Guilford and Diane Glazer Bloomberg Financial Markets Marvin and Barbara Davis Alan and Marlene Gleicher Commodities News Roger J. Davis Seth Glickenhaus Bloomberg L.P. Michel De Beaumont Colin Goddard, Ph.D. Burton Borman Joseph J. Dempsey Bradley and Sunny Goldberg Albert R. Boscov Terr y Diamond Michael A. Goldberg Boston Red Sox Richard DiMeola Andy Goldfarb G. Michael Boswell Don King Productions, Inc. R. Anthony Goldman Reggie Bowerman Donaldson, Lufkin & Jenrette Russell D. Goldsmith Steve Braverman Carl Doumani Eric Goldstein Bernard and Judy Briskin David H. Dreyfuss Michael Goldstein Harry M. Brittenham, Esq. Dunwoody Country Club The Golfworks Brooklyn Hospital Center Alvin Dworman Litto Gomez John M. Bryan Eastdil Realty, Inc. Edward and Cheryl Gordon Bryanston Group, Inc. Charles Edelstein Berry Gordy, Jr. Kurt W. Butenhoff Stephen Einhorn Jerome and Shirley Gore Bernie F. Butler Lee Einsidler Abraham D. Gosman Michael Butler Steve Eiseman Fredric Gould Canyon Partners David F. Eisner Mark Grant Michael Caridi Roger A. Enrico Madison and Susan Graves Liam Carlos Mike Ensign George D. Grayson Johnny Carson Jeff Epstein George L. Graziadio Donald and Nancy Carter Mr. and Mrs. Robert S. Evans Steven and Dorothea Green Edwin P. Carter Evergreen Foundation Gary and Sandra Grimes Marx L. Cazenave II Federated Department Stores Julie Groshens Irwin Chafetz Foundation Michael S. Gross Chartwell Foundation Brad Felenstein David and Leslie Hahn Peter Chernin Robert M. Fell Brian L. Halla Andrew S. Clare Mike Ferry James A. Harmon Coca-Cola Co. Mark Finerman Richard J. Harrington Harold K. Cohen Gerald B. Finneran Mel Harris Jerry and Adrianne Cohen Jerome and Anne Fisher William B. Harrison, Jr. Jim and Marcia Colbert Larry and Kathleen Fisher Richard C. Hartnack Gregory and Monica Coleman Lester and Gwen Fisher William Hartnett Commerce Bank, North, N.A. Richard Fisher Albert and Irene Hartog Jimmy and Patti Connors Joseph Flom Richard J. Heckmann James and Nancy Cook Steven T. Florio Andrew L. Heiskell David N. Corleto Lynn Forester Bruce Heller Jack B. Corwin Michael G. Foster, Jr. Jane Heller Ken Cory Foxsports.com Jerry Hennessy Robert H. Cosgriff Lionel Frais Lawrence Herbert Terr y Cosgrove Frances and Jack Levy Foundation Leon and Norma Hess Credit Suisse First Boston Corporation Paul Fribourg Andrew R. Heyer Alberto Cribiore Steven Friedman H.J. Heinz Company Cuba Club Larry H. Friend H. S. Hoffman Chip Cushman Peter Fudge Beth Hollfelder Theodore Cutler Jeffrey Furman Butch Holmes Cytogen Corporation Frederick and Peggy Furth Homayoun Homampour Dabney/Resnick Imperial Ronald H. Galowich Home Box Offi ce John Daly General Nutrition Centers D. E. Brice Howe The David and Sheila Cornstein Arie Genger Helmut Huber Foundation Charles, Jr. and Vivian Gillespie Gene Humphrey Prostate Cancer Foundation 53 53

Michael Hyatt LS Management Larry R. Palmer, CEP, CTP Royce Imhoff Rufus and Patricia Lumry Chuck Palombini International Financiers, Inc. Jerome D. Mack Norman J. Pattiz Herb W. Jacobs Macy’s Paul, Weiss, Rifkind, Sheldon Jacobs John Magliocco Wharton & Garrison, LLP Ron Jacoby Peter A. Magowan David Pecker Mr. and Mrs. Robert M. Jaffe Mandalay Resort Group Gerry Pencer James S. Riepe Family Foundation Mandelbaum Foundation Arthur Penn Jeffery & Nancy Lane Foundation, Inc. Mel Mannion Ethan Penner Michael and Linda Jesselson Bernard Marcus Pensions 2000 Clark A. Johnson Howard and Stacy Marks Leonard C. Perham Allen N. Jones Kenneth Mazik Phoenix Home Life Mutual Ellis B. Jones Larry Mazzola Insurance Company The Judy and Howard Berkowitz Les G. McCraw, Jr. Albert and Jeanine Pirro Foundation John and Constance McGillicuddy Michael A. Pitino Mitch Julis Thomas J. McKearn Mack Pogue Harold Sanford Kant, Esq. Kara McKinley Pohlad Family Charities Donna Karan and Stephen Ruzow J. P. McManus William J. Polvino, M.D. Peter M. Kash James A. McRae Steve Posner Howard and Susan Kaskel Medco Containment Co. Maury Povich and Connie Chung David and Silvana Kay Keith Meister Michael J. Price Joshua and Joia Kazam Todd Meister Wayne Prim, Jr. Dean C. Kehler Prakash Melwani Jay Pritzker Solomon Kerzner Arnon Milchan Prometheus International, Inc. Gregory F. Kiernan Lee S. Millstein Alan Quasha Brian King Milton H. Dresner Bruce I. Raben Joel and Michele Kirschbaum Charitable Foundation Ed W. Rabin Daniel J. Kleiman Larry A. Mizel Bruce Ratner Calvin Klein Robert Michael Mondavi Michael Ratner Michael and Patricia Klowden Charles K. Monfort Randolph and Lindsey Read Harold and Shirley Kobliner Eugene Monkarsh John S. Reed A. B. Krongard David Moore Denise Rich Mark Kurland Jerry Moss Harold W. Ripps Herbert and Edyth Kurz Mr. & Mrs. Robert Baker Brian L. Roberts Gerrity Lansing Family Foundation Ralph J. Roberts Leonard and Evelyn Lauder Wayne Mueller James D. Robinson III William P. Lauder Donald R. Mullen Rodney Strong Vineyards Steve Lawrence and Eydie Gorme Peter Mullin Gerald Ronson Norman Lear Bill Mundell Allison Rosen Lederman Family Foundation Naples Drive for the Cure Fredric and Rikki Rosen Don and Rita Lee Menasche M. Nass Byron Roth Stephen R. Leibowitz Albert Neale James Rothstein Len and Barbara Darling Family Fund Rooney Nelson Round Hill Country Club Alfred and Norma Lerner New England Financial Michel Roux Julius and Miriam Lesner Wayne and Kathleen Newton James Russell Frederick N. Levinger NFL Charities Steve Sanak Richard Levy Perry Nisen, M.D., Ph.D. Raymond C. Sandler Loida N. Lewis Northern California District Richard Sandor Robert Lienau Council of Laborers Sylvan Schefl er Arthur Liman Marlene Nusbaum Andrew Scheinman Steven Lipman T. D. O’Connell David Schneider David B. Lowry Cindy K. Olson Raymond D. Schoenbaum 54 54 Prostate Cancer Foundation

Lewis M. Schott Charles and Adele Thurnher R. Jack Alexander, Jr. Ian Schrager Andrew H. and Ann Tisch Allied Beverage Group, LLC Michael and Paola Schulhof James S. Tisch Arthur G. Altschul, Jr. Charles and Helen Schwab Steven H. Tishman Ellsworth C. Alvord III Alan D. Schwartz Dennis A. Tito Richard and Nancy Alvord Schwartz, Kales Accountancy Corp. John T. Toland John Angelo Ted Schwartz Robert Toll Tom Armstrong Charles Scott Joe and Alice Torre The Arthur Loeb Foundation Russell Scott, Jr. Richard P. Torykian, Sr. Phillip Asherian Tony Scotti Jesse I. Treu Michael and Sheila Ashkin Security Life Inc. Group Prabhakar Tripuraneni, M.D., FACR Sherrell and Muffi e Aston Ivan G. Seidenberg The Trump Organization Rick G. Avare Mike Shad Tudor Investment Corporation Bacardi Limited Michael Shapiro Valquip Corporation Pam Balton Shearman & Sterling Karen van Nouhuys Martin Bandier Howard Shecter Mary T. Venable Scott P. Barasch Mark Shenkman The Vons Companies Charitable Alexander E. Barkas and Lynda Wijcik Robert D. Shipp Foundation, Inc. Janice Barney Boaz Shonfeld Rosemary Vrablic The Barrack Foundation Walter Shorenstein Don Vultaggio Michael J. Batza, Jr. Stan Shuster Shirlene A. Wainer Charles and Ruth Bauer Stanley J. Sidel Ira Walker Ted and Ruth Baum Sanford C. Sigoloff Stephen and Maura Walsh Lee Beattie Eugene Silverman William and Claudia Walters Bradley Bell Jay B. Silverman Kenneth Wang John and Cathi Bendheim Thomas M. Simms Casey and Laura Wasserman Walt L. and Lee Bent Mark J. Simon Tom Watkins Elliot Berger and Mary Schroeder Ted Simpkins Scott Watt Martin S. and Karen Berger Sirens Society Michael Weinstein Leonard H. Bernheim, Jr. Charles B. Slack Robert F. Weis The Betsy and Alan Cohn Alan B. Slifka Melvyn I. Weiss Foundation, Inc. John F. Smith, Jr. Morris Weissman Anthony J. Bettencourt Snyder Weiner Weltchek & Vogelstein Whittemore Family Foundation William C. and Sandra Bevins Marilyn Sobel Ralph and Wendy Whitworth Fred B. Bialek Bruce Sokoloff Arthur Wiener Les and Lynn Bider Bob Solomon Henry Wilf Marc Blackman Warren J. Spector Fred Wolf Michael and Nina Blechman Allison Speer C. Tal Wooten, Jr. Tim and Edra Blixseth Aaron and Candy Spelling Gerard Yvernault James A. and Barbara Block Jerry Speyer Louis G. Zachary, Jr. Ron Boeddeker Irwin and Lorri Spiegel Jeffrey Dunston Zients Franklin Otis Booth, Jr. Lawrence Spira, M.D. Roy Zuckerberg Kurt T. Borowsky Jeffrey Steiner Robert A. Zummo Richard Boughner Irving Stenn Larry Bowman Lawrence Sheldon Stroll Contributors Thomas S. Bowman Melanie Sturm ($5,000 – $9,999) Leonard Boxer Sanford and Charna Sugar Robert J. Abt Stephen M. Brett Katharyn Swintek The Adler Family Foundation, Inc. Pam Brill Tag Associates, LLC Advance Shared Services Center Nancy Brinker Jeremiah and Nonie Tarr AIM Management Group Edward Brodsky Fredricka Taubitz Alvin R. Albe Jeffrey and Susan Brown Anthony Terlato Ellis J. Alden Richard A. Brown Prostate Cancer Foundation 55 55

Christopher H. Browne Andrew Farkas Edward and Gaye Hewson Richard C. Browne Jonathan Farkas Roderick and Carla Hills Bruce E. and Robbi S. Toll Foundation Irving Feintech Douglas Hirsch and Holly Anderson Marc R. Brutten Robert M. Fell Peter A. Hochfelder Deborah L. Burger, Inc. James A. Ferency Richard and Jackie Hollander Jack Burstein Elliot Feuerstein Gerald Horowitz Richard Byrd Gregory and Linda Fischbach Joe Howe California Community Foundation Richard B. Fisher Mark Hughes Phil Caputo Stephen B. Fiverson Wayne and Marti Huizenga Frank L. Cassidy, Jr. Karen A. Flann and Homer Schwartz James and Susan Husband Cell Genesys, Inc. Dennis Flatt George Hutchinson Clive Chajet Sam Forman Lee Iacocca Michael J. Charles Gayle Devers Fortune Institute for Health & Productivity Sophie Chen, Ph.D. David Foster Management Bernd Chorengel Michael Frankel Hale S. Irwin City National Bank Joel Friedland Jeremy Jacobs Clarium Capital Management, LLC Josh and Beth Friedman Nathan P. Jacobs Clark & Weinstock Stephen Friedman Leonard R. Jaskol Greg Clark Robert and Ann Fromer Max Javit Bert and Marilynn Cohen Richard S. Fuld, Jr. J. C. Earle Family Fund Joseph M. Cohen Roy Furman Gordon W. Jenkins Richard D. Cohen Tom W. Gamel Charles Jennings Victor A. Cohn Howard Ganek JFD / MJD Golf Open Michelle A. Connelly Lloyd and Laurel Garver James and Lorene Jimmerson Elaine Terner Cooper Genentech, Inc. Matthew J. Kahrhoff John Cooper, Jr. Georgetown Tobacco & Pipe Stores, Inc. Kaiser Permanente Stephen A. Cooper, DMD, Ph.D. S. William and Barbara Gersten Thomas J. Kalinske Peter Coors Tom Giovanelli Walter Karabian Fred Corrado The Honorable Rudolph W. Giuliani Bruce and Sandra Karatz Marshall B. Coyne Arthur M. Goldberg Stanley and Marilyn Katz Gregory Cuneo Howard Goldenson Stephen Katz The Daniel Veloric Foundation Steve A. Goldfarb George Kaufman Ed DeBartolo, Jr. Kenneth and Barbara Goldman Gershon Kekst Delcal Enterprises, Inc. Richard Goodwin Donald H. Keltner Jerry Della Femina John R. Gordon Ken Roberts Company Robert Dodson Louis and Nancy Grasmick J. Christopher Kennedy Drexel University Jim Grau Keys Foundation Daniel A. Duc Mark Greenhill Michael G. King, Jr. Gregory and Eileen Duch Howard and Dana Gurvitch Burton Koffman Raymond Duncan Lynn M. Haff Oswaldo Kosta Joseph and Carol Ann Dvorak John Hagestad Robert Kraft Walter Eberstadt Hall Dickler Kent Goldstein & Jules B. Kroll Spencer F. Eccles Wood, LLP Norman D. Kurtz Maurits and Claire Edersheim Jesse Halperin Laborers’ International Union - Anders B. Eklov Fred Hameetman El Monte Local 1082 Mr. and Mrs. Alfred Engelberg Mark S. Handler Laborers’ International Union, Local 270 Robert and Nancy Engelberg Mark S. Hanson Laborers’ International Union of Yan Erlikh Martin Aaron Harmon North America-Local 300 Aaron R. Eshman Gilbert and Shelley Harrison Fred S. Lafer Linda Evangelista Lauren M. Hartman Robert F. Lampe, Jr. William F. Evans Kay Hemingway Ken Langone Samer Farah, M.D. Michael B. Hershey Robert Larner, M.D. 56 56 Prostate Cancer Foundation

Latham & Watkins Harve H. Mossawir, Jr. and Judy Bardugo Thomas A. Roberts Ronald and Jo-Carole Lauder Paul Motenko James and Linda Robinson The Laura Steinberg Tisch Charles H. Mott Sam and Mary Robson Foundation, Inc. Joseph M. Murphy Iber Rodriguez Lynn M. Leany Alan C. Myers Stephen M. Ross Frank Leanza Douglas P. Nation Gordon Roth Ken Leese David Nazarian Edward F. Rover Charles E. Leonard III Marty Nealon R. S. Evans Foundation, Inc. Steve Leonard Lee and Joyce Neibart Richard Ruben Warner LeRoy Mary-Rose Nelson Edward and Sally Rust Margaret Lesher Nestlé Waters North America, Inc. Denny Ryerson John A. Levin Blake Lee Neubauer, Ph.D. Thomas L. Safran Neil Levine Shilom Neuman Max Salter John S. Levy Chuck Nicolette, M.D. Allan and Emily Sanders David Liebowitz Niebaum-Coppola Estate Winery Theodore and Alison Sands Sio Lindner Douglas and Nancy Norberg Patrick Savin Samuel S. Lionel Greg Norman Al Scheid The Litwin Foundation, Inc. Nsuh Foundation Schmertz Company, Inc The Loa Productions, Inc. Obermeyer Asset Management Alfons J. Schmitt John L. Loeb, Jr. Company David M. Schoenthal Shumer Lonoff James T. O’Brien Marvin I. Schotland Bob Lorsch Morris Offi t David K. Schulhof Lyncar Enterprises, Inc. John O’Hurley Robert Schulman John Magnier Marvin Olshan Marvin H. Schur Anthony J. Magro Shepard Osherow Gerald and Elaine Schuster Brian A. Maki Donald P. Pakosh Governor Arnold Schwarzenegger Idelisse Malave Donald and Rhoda Parmet and Maria Shriver Judd Malkin Partners Marketing Group Lisa White Schweitzer Shareef Malnik Randall Eric Paulson Peter W. Schweitzer George J. Maloof David R. Pedowitz Henry Seiden Stuart Manheim, CPA James C. Pendergast Dr. Michael E. Seiff Stephen J. Marcus Mark Perlbinder Martin Selig Bernard A. Marden Charles Persico Michael S. Shannon Ken Martin Robert E. Petersen Robert and Linell Shapiro Kim Martindale Pharmaceutical Research and Thomas and Medeleine Sherak Elliott Masie Manufacturers of America Sheri and Marc Rapaport Fund Norman and Joanne Matthews Rick Pitino Pam Shriver Giacomo Mattoli Ed Prager Herbert J. Siegel Caryn Mautner Wayne Prim, Sr. William Siegel Marilyn McCoo and Billy Davis, Jr. Edward Probyn Adrianne W. Silver Liam E. McGee Bob Pryt Richard Silverman Robert J. McNulty John A. Ptak Ronald A. Simms Rolf Meijer-Werner Kjell H. Qvale David Simon Merrill Lynch & Company Robert E. Racicot Dick Simon Foundation, Inc. Steve Rader James D. Sinegal David A. Miller Raley’s Gold Rush Classic John C. Sites Honorable Robert Joseph Miller Max Ramberg Van Skilling Peter H. Mills Donald Rechler Joel E. Smilow Phillip S. Mittelman Scott Gregg Rechler Gordon Smith Arthur and Patricia Modell Joseph P. Riccardo Jeff N. Smith James J. Moglia W. Brent and Brenda Rice Arnold Snider David Moore Robin Richards Steve Snyder Raymond Moore Richard A. Rigg Southern Company Services, Inc. Morongo Band of Mission Indians Ritz-Carlton Southern Wine & Spirits of Nevada, Inc. William S. Morris III Ritz-Carlton Boston Larry Spitcaufsky Morton’s Restaurant Group Kenn Roberts Starbucks Coffee Company Prostate Cancer Foundation 57 57

John Stark Pharmaceutical, Biotechnology Joseph Stein and Device Sponsors Steven E. Stern The Stone Family Fund PCF Pharmaceutical Thomas W. Strauss Industry Roundtable Nancy C. Stricklin Abbott Laboratories Chris Stuhmer Aventis Sunbelt Beverage Company, LLC Novartis Oncology Dennis A. Suskind Sanofi -Synthelabo Don Swirnow Roberta R. Tanenbaum 11th Annual Scientifi c Retreat Stanley G. Tate Gold Sponsors: Ian Ross Taylor Abbott Laboratories Walter D. Tearse Aventis Vincent Tese Bristol-Myers Squibb Company Thomas S. Henderson and Sally S. Novartis Oncology Henderson Foundation OSI Pharmaceuticals Chuck B. Thornton, Jr. Silver Sponsors: TJH Millennium Stanley T. Trotman, Jr. Sanofi -Synthelabo Cecily Truett Mark Truitt Other Jeffrey H. Tucker Cytogen Corporation Turner Broadcasting System, Inc. Dendreon Alfred Tyler II Oncura Peter V. Ueberroth Ortho Biotech, Inc. William D. Unger Tibotech Therapeutics Tom Unterman TomoTherapy, Inc. Michael J. Urfi rer Varian Medical Systems, Inc. Neil G. Van Luven Basil K. Vasiliou Velos Medical Informatics, Inc. Mary E. Venable Robert A. Waller David E. Walters John Walton William R. Ward Jack L. Warner Roger Weber Raymond J. Weis Robert Weiss Jay Weitzman Miles D. White Gary L. Wilson Daniel P. Wimsatt Andrew Wise Moira Wolofsky Douglas J. Wood Rodney A. Wray Bud and Cynthia Yorkin Stan Zicklin 58 58 Prostate Cancer Foundation

PRESIDENTIAL BOARD BOARD OF DIRECTORS

Mike Milken Founder and Chairman Prostate Cancer Foundation

James Blair General Partner Domain Associates

Gerald Ford S. Ward (Trip) Casscells III, M.D. John Edward Tyson Distinguished Professor of Medicine and Vice President of Biotechnology University of Texas HSC, Houston

David Ederer Chairman Ederer Investment Company

Sue Gin Chairman and Chief Executive Offi cer Jimmy Carter Flying Food Group, Inc.

The Reverend Rosey Grier The Milken Family Foundation

Andrew Grove Chairman Intel Corporation

Stuart Holden, M.D. Director Cedars-Sinai Louis Warschaw George H.W. Bush Prostate Cancer Center Warschaw, Robertson, Law Families Chair in Prostate Cancer Cedars-Sinai Medical Center

Arthur Kern Investor

David Koch Executive Vice President Koch Industries Bill Clinton Jeffrey A. Marcus Partner Crestview Capital Partners

Shmuel Meitar Director Aurec Group 59

Lori Milken EXECUTIVE MANAGEMENT Vice President Prostate Cancer Foundation Leslie D. Michelson Vice Chairman and Nelson Peltz Chief Executive Offi cer Chairman and Chief Executive Offi cer Ralph Finerman Triarc Companies, Inc. Secretary, Treasurer and Chief Financial Offi cer Lynda Resnick Vice Chairman Debbie J. Bohnett Roll International Chief Operating Offi cer

Robin Richards Craig Dionne, Ph.D. Chairman and Executive Vice President Chief Executive Offi cer of Research and Therapeutics Notifi cation Technologies Stuart Holden, M.D. Bert Roberts Medical Director Consultant Gregg S. Britt Richard Sandler Senior Vice President, Partner Biopharmaceutical Maron and Sandler Research and Development Executive Vice President The Milken Family Foundation Karen Stone Senior Vice President, J. Gary Shansby Development Founder The Shansby Group Scott Harvey Senior Vice President, Lester H. Smith Corporate Alliances Chief Executive Offi cer Smith Energy Company Sarah Z. Evans Vice President, Michael L. Tarnopol Communications Vice Chairman Bear, Stearns & Co. Inc. Jan Haber Vice President, Events Robert Voss and Donor Relations President Fox Packaging Company Helen Hsieh Vice President, Finance Jerry Weintraub and Administration President Jerry Weintraub Productions Martin Erck Vice President, Special Projects Elaine Wynn Co-Chief Executive Offi cer Wynn Resorts

Stanley Zax Chairman and President Zenith National Insurance Company 60 Prostate Cancer Foundation

APPEAL FOR SUPPORT The PCF is making measurable strides to beat cancer, but to reach the ultimate goal—a cure for recurrent prostate cancer—we need your help.

To defeat prostate cancer once and for all, the PCF is commit- ted to harnessing as many human and fi nancial resources as possible. This includes corporations, major donors and, yes, you. Everyone can, and does, make a difference.

It takes all kinds of people to support the PCF. People whose loved ones—husbands, fathers, brothers, sons—have pros- tate cancer. People worried that one day they, or other men in their lives, will be diagnosed with this all-too-common disease. Industry leaders. Famous athletes. The man on the street.

With your help, we will fi gure out why so many men get prostate cancer, and why it is far more life-threatening to some men than to others.

With your help, we will bring down the current barriers to completing clinical trials for new prostate cancer drugs and win regulatory approval for them.

With your help, we will make sure that every man with prostate cancer has access to the latest treatments and that doctors treating the disease are up-to-date on the most current advances in care.

With your help, we will provide vital early funding for exper- imental prostate cancer treatments for intractable cases of advanced prostate cancer.

There’s no time to waste, so please act now.

The PCF welcomes memorial or tribute gifts in honor of friends or loved ones, as well as monetary donations, donations of non- cash assets and bequests. Donations

Please mail your check to: Prostate Cancer Foundation 1250 Fourth Street Santa Monica, California 90401

To make an online contribution, please visit our Web site: prostatecancerfoundation.org.

To make a credit card donation, call 800.757.CURE.

Memorial or Tribute Gifts

Honor the memory of a loved one or celebrate the accomplish- ment of a friend or family PCF member by helping others. 2004 WAS A REMARKABLE YEAR. Make a memorial or tribute gift and the PCF will send an Fortune featured the PCF in its November cover story acknowledgment card to the entitled “Beating Cancer,” and named the PCF as its offi cial family of the honoree. philanthropy to celebrate its 75th anniversary. Other Gift Suggestions For the fi rst time ever, the U.S. Food and Drug Adminis- tration approved a drug (Taxotere) that extends life for men Assets or property including with advanced prostate cancer. appreciated stock and real estate.

The PCF expanded its donor base by 35%. Bequest—Include a gift to the PCF in your will. And, signifi cant progress was made in demonstrating the link between nutrition, especially antioxidants, and Name the PCF as the primary prostate cancer. or contingent benefi ciary on a life insurance policy.

Editors: Sarah Evans, Jessica Niebauer Contributor: Jon Greer Special Thanks: Aaron Ciechanover, M.D., D.Sc., Steve Burd, Don Coffey, Ph.D. , Rosey Grier, Beth Kobliner Shaw, Nelson Peltz, Marvin R. Shanken, Wade F.B. Thompson, Joe Torre Photography: Michael D’Ambrosia Design: KBDA, Los Angeles More information: www.prostatecancerfoundation.org iProstate Cancer Foundation Annual Report 04

1250 Fourth Street Santa Monica, California 90401 Tel 310.570.4700 Fax 310.570.4701 www.prostatecancerfoundation.org